Jade Biosciences, Inc. Common Stock JBIO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.05M+26.3% | $28.54M+29.7% | $22.01M-2.4% | $22.55M+12.6% | $20.02M-35.9% | ||
| $7.39M+14.8% | $6.44M+19.4% | $5.39M+3.1% | $5.23M+55.6% | $3.36M-21.9% | ||
| $43.45M+24.2% | $34.98M+27.7% | $27.4M-1.4% | $27.78M+18.8% | $23.38M-34.2% | ||
| -$43.45M-24.2% | -$34.98M-27.7% | -$27.4M+1.4% | -$27.78M-18.8% | -$23.38M+34.2% | ||
| $3.09M— | —— | $2.23M+151% | -$4.36M+70.5% | -$14.79M-29.2% | ||
| -$40.35M— | —— | —— | —— | -$38.17M+18.8% | ||
| $16K+10.3% | $14.5K0.0% | $14.5K0.0% | $14.5K0.0% | $14.5K— | ||
| -$40.37M-26.4% | -$31.93M-26.8% | -$25.18M+21.7% | -$32.13M+15.8% | -$38.17M+18.8% | ||
| -$0.57-418% | -$0.11+77.1% | -$0.48+44.2% | -$0.86+92.9% | -$12.10+18.7% | ||
| -$43.44M-24.2% | -$34.97M-27.7% | -$27.39M+1.4% | -$27.78M-18.8% | -$23.38M+34.2% | ||
| -$43.45M-24.2% | -$34.98M-27.7% | -$27.4M+1.4% | -$27.78M-18.8% | -$23.38M+34.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Jade Biosciences, Inc. Common Stock profitable?
- Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's earnings per share?
- Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
- Where does Jade Biosciences, Inc. Common Stock's income statement data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.